***COVID-19 VACCINE ANALYSIS***

***Innovation:***

Innovation and patenting activities of COVIO-19 accines: Analytical review of Medicines Patent Peel (MPP) COVIO-19 Vaccines Patent Landscape (VaxPaL)

This werking paper provides a statistical analysis of 74 patent Familles which cover subject matter relevant to ten COVIO-19 Vaccines. These vaccines Have accounted For 99% of the global COVIO-19 Vaccine production as F 31 December 2021. comprising wter ten Billion doses.

Eight of them, namely BAT16282 (Pfizer/BinTech), AZ01222 (AstraZeneca/Oxford). Ad26.00V2-8 (989) mRNA-1273 (Moderna). 8818P-Cerv (Sinepharm/Beijing). Cerenatac (Sinviac). Celaxin (Bharat/ICMR), and VX-CV2373 (notatax), hate Been appreted By the World Health Organization (WHO) For inclusion in Its Emergency Use Listing (ELL). The analysis is based on VaxPal, a COVIO-19 Vaccines patent database developed by the Medicines Patent

(MPP). Through the detailed examination of patent applicants, Filing dates, and offices of First and subsequent Filing, the paper Identifies patterns and trends of Innovation and patenting activities of COVIO-19 vaccines in WTO members, and presents the legal status of the 74 patent Families in 105 jurisdictions. This information may provide useful Background for policymakers on the significance and potential impact of these patent Families with relevance to the access to and production of these vaccines in their individual countries. This, In turn, may help support practical assessments as to potential options within and Beyond the current TRIPS Framework to promote equitable access to COVIO-19 Vaccine